patient with Photodamage skin at face facial rejuvenation, Calcium Hydroxylapatite
Conditions
Interventions
Calcium Hydroxylapatite (CaHA) Injection was injected to patient face. Patient was then follow up at 1,3 6,9 and 12 months after complete treatment
Experimental Device
Calcium Hydroxylapatite (CaHA) Injection
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
25 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. age 25 to 60 years male and female 2. moderate degree of photoaging assed by dermatologist Glogau classification of photoaging 3. Asian descend 4. consent to receive treatment and following as protocol
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women. 2. Volunteers with a history of abnormal platelet disorders or abnormal blood clotting, anemia, liver disease, cancer, autoimmune deficiency. 3. Volunteers who smoke and have a history of heavy alcohol consumption. 4. Volunteers with inflammatory skin rashes (dermatitis), wounds, or infected skin on the face. 5. Volunteers with a history of local anesthetic allergy. 6. Volunteers with a history of taking hormones or contraceptives, including injectable forms or regular NSAIDs. 7. Volunteers with a history of taking medications that affect blood clotting, such as aspirin and anticoagulants. 8. Volunteers with a history of facial lifting procedures, including lifting devices or thread lifting, within 6 months prior to joining the research project. 9.Volunteers who have had facial fillers injected within 6 months before joining the research project. 10.Volunteers who have had injections of concentrated platelet-rich plasma in the face within 6 months before joining the research project. 11. Volunteers who have had botulinum toxin injections in the face within 6 months before joining the research project. 12.Volunteers who have undergone facial collagen-stimulating laser treatments, such as Picosecond laser, Erbium: YAG laser, Fractora, or Laser E matrix within 6 months before joining the research project. 13.Volunteers with hypertrophic scars. 14.Volunteers with a diagnosed mental disorder by a psychiatrist. 15.Volunteers who do not consent to having photographs taken for treatment assessment. 16.Volunteers with a history of allergy to calcium hydroxyapatite.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| wrinkle baseline, 1-,3-,6-,9- and 12- month after complete treatment antera,texture baseline, 1-,3-,6-,9- and 12- month after complete treatment antera,WSRS baseline, 1-,3-,6-,9- and 12- month after complete treatment score | — |
Secondary
| Measure | Time frame |
|---|---|
| volume change baseline, 1-,3-,6-,9- and 12- month after complete treatment vector,volume change baseline, 1-,3-,6-,9- and 12- month after complete treatment quantificare,skin elasticity baseline, 1-,3-,6-,9- and 12- month after complete treatment Cutometer,melanin baseline, 1-,3-,6-,9- and 12- month after complete treatment mexameter,erythema baseline, 1-,3-,6-,9- and 12- month after complete treatment mexameter,hydration baseline, 1-,3-,6-,9- and 12- month after complete treatment corneometer,ITA baseline, 1-,3-,6-,9- and 12- month after complete treatment colorimeter,sebum baseline, 1-,3-,6-,9- and 12- month after complete treatment sebumeter,adverse event baseline, 1-,3-,6-,9- and 12- month after complete treatment note,patient improvement score baseline, 1-,3-,6-,9- and 12- month after complete treatment GAIS,pain score treatment visual analog scale | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed